

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6828828/jos-jonkers-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

227 papers	22,552 citations	76 h-index	146 g-index
284 ext. papers	26,888 ext. citations	13.3 avg, IF	6.58 L-index

#	Paper	IF	Citations
227	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016 , 534, 47-54	50.4	1193
226	Patient-derived xenograft models: an emerging platform for translational cancer research. <i>Cancer Discovery</i> , 2014 , 4, 998-1013	24.4	1018
225	IL-17-producing T cells and neutrophils conspire to promote breast cancer metastasis. <i>Nature</i> , 2015 , 522, 345-348	50.4	900
224	Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. <i>Nature Genetics</i> , 2001 , 29, 418-25	36.3	807
223	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. <i>Nature Structural and Molecular Biology</i> , 2010 , 17, 688-95	17.6	707
222	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 17079-84	11.5	707
221	Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. <i>Cell</i> , 2014 , 159, 499-513	56.2	542
220	Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. <i>Cancer Cell</i> , 2006 , 10, 437-49	24.3	466
219	Replication fork stability confers chemoresistance in BRCA-deficient cells. <i>Nature</i> , 2016 , 535, 382-7	50.4	456
218	Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 9209-14	11.5	451
217	Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. <i>Molecular and Cellular Biology</i> , 2006 , 26, 5015-22	4.8	432
216	The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. <i>Nature Reviews Cancer</i> , 2012 , 12, 587-98	31.3	415
215	REV7 counteracts DNA double-strand break resection and affects PARP inhibition. <i>Nature</i> , 2015 , 521, 541-544	50.4	376
214	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017 , 17, 254-268	31.3	369
213	Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. <i>Cancer Discovery</i> , 2013 , 3, 68-81	24.4	346
212	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 12111-6	11.5	343
211	Long-term expanding human airway organoids for disease modeling. <i>EMBO Journal</i> , 2019 , 38,	13	336

210	Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. <i>EMBO Journal</i> , 1999 , 18, 4233-40	13	325
209	A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. <i>EMBO Reports</i> , 2001 , 2, 292-7	6.5	286
208	The shieldin complex mediates 53BP1-dependent DNA repair. <i>Nature</i> , 2018 , 560, 117-121	50.4	277
207	Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. <i>Molecular and Cellular Biology</i> , 2004 , 24, 6104-15	4.8	262
206	Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. <i>Clinical Cancer Research</i> , 2008 , 14, 3916-25	12.9	258
205	Conditional mouse models of sporadic cancer. <i>Nature Reviews Cancer</i> , 2002 , 2, 251-65	31.3	242
204	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 12117-22	11.5	241
203	PARP Inhibitor Efficacy Depends on CD8 T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019 , 9, 722-737	34.4	222
202	Human and mouse oligonucleotide-based array CGH. <i>Nucleic Acids Research</i> , 2005 , 33, e192	20.1	219
201	Genetically engineered mouse models in oncology research and cancer medicine. <i>EMBO Molecular Medicine</i> , 2017 , 9, 137-153	12	218
200	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1529-44	16.6	197
199	CIP2A is associated with human breast cancer aggressivity. <i>Clinical Cancer Research</i> , 2009 , 15, 5092-100	12.9	190
198	BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. <i>Cancer Cell</i> , 2011 , 20, 797-809	24.3	187
197	Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. <i>Oncogene</i> , 2006 , 25, 5885-97	9.2	180
196	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. <i>Nature Cell Biology</i> , 2017 , 19, 1371-1378	23.4	179
195	Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. <i>Nature</i> , 2019 , 572, 538-542	50.4	173
194	How do real tumors become resistant to cisplatin?. <i>Cell Cycle</i> , 2008 , 7, 1353-9	4.7	168
193	BRD7 is a candidate tumour suppressor gene required for p53 function. <i>Nature Cell Biology</i> , 2010 , 12, 380-9	23.4	161

192	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 1203-1210	10.3	160
191	NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. <i>EMBO Journal</i> , 2008 , 27, 2603-15	13	157
190	Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping. <i>Nature Biotechnology</i> , 2014 , 32, 1019-25	44.5	152
189	Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. <i>Cell</i> , 2008 , 133, 727-41	56.2	149
188	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. <i>Nature Genetics</i> , 2007 , 39, 759-69	36.3	148
187	Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. <i>Physiological Genomics</i> , 2007 , 31, 32-41	3.6	142
186	Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. <i>Cancer Cell</i> , 2018 , 33, 1078-1093.e12	24.3	139
185	An E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. <i>Journal of Pathology</i> , 2013 , 229, 621-9	9.4	138
184	CopywriteR: DNA copy number detection from off-target sequence data. <i>Genome Biology</i> , 2015 , 16, 49	18.3	136
183	The BRCA1- Δ 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. <i>Cancer Research</i> , 2016 , 76, 2778-90	10.1	136
182	Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. <i>Cancer Research</i> , 2002 , 62, 1862-7	10.1	135
181	A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. <i>Nature Protocols</i> , 2009 , 4, 789-98	18.8	128
180	Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland. <i>Journal of Pathology</i> , 2012 , 228, 300-9	9.4	121
179	Mutagenic insertion and chromosome engineering resource (MICER). <i>Nature Genetics</i> , 2004 , 36, 867-71	36.3	121
178	High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. <i>Cancer Research</i> , 2009 , 69, 3625-33	10.1	120
177	BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. <i>Nature Structural and Molecular Biology</i> , 2010 , 17, 1461-9	17.6	119
176	Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. <i>Clinical Cancer Research</i> , 2014 , 20, 4816-26	12.9	111
175	Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?. <i>Clinical Cancer Research</i> , 2014 , 20, 540-7	12.9	108

174	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	108
173	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. <i>DMM Disease Models and Mechanisms</i> , 2011 , 4, 347-58	4.1	104
172	Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. <i>Current Biology</i> , 2008 , 18, 1094-9	6.3	102
171	Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas. <i>EMBO Journal</i> , 1997 , 16, 441-50	13	101
170	EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. <i>Breast Cancer Research</i> , 2008 , 10, R109	8.3	99
169	Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. <i>Gut</i> , 2012 , 61, 344-53	19.2	96
168	HELB Is a Feedback Inhibitor of DNA End Resection. <i>Molecular Cell</i> , 2016 , 61, 405-418	17.6	92
167	A high-throughput functional complementation assay for classification of BRCA1 missense variants. <i>Cancer Discovery</i> , 2013 , 3, 1142-55	24.4	92
166	Retroviral insertional mutagenesis as a strategy to identify cancer genes. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1996 , 1287, 29-57	11.2	92
165	What makes tumors multidrug resistant?. <i>Cell Cycle</i> , 2007 , 6, 2782-7	4.7	89
164	Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. <i>Nature Medicine</i> , 2012 , 18, 344-6; author reply 346	50.5	88
163	BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. <i>Breast Cancer Research</i> , 2009 , 11, R63	8.3	86
162	Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. <i>Cancer and Metastasis Reviews</i> , 2018 , 37, 577-597	9.6	86
161	Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. <i>Journal of Clinical Investigation</i> , 2011 , 121, 3176-88	15.9	85
160	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	85
159	Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. <i>Genes and Development</i> , 2016 , 30, 1470-80	12.6	84
158	The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. <i>Cancer Cell</i> , 2018 , 34, 197-210.e5	24.3	82
157	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 8409-14	11.5	81

156	Targeting homologous recombination repair defects in cancer. <i>Trends in Pharmacological Sciences</i> , 2010 , 31, 372-80	13.2	81
155	Easy quantification of template-directed CRISPR/Cas9 editing. <i>Nucleic Acids Research</i> , 2018 , 46, e58	20.1	80
154	BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2903-18	15.9	80
153	Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. <i>Cancer Research</i> , 2009 , 69, 6396-404	10.1	79
152	Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. <i>Radiotherapy and Oncology</i> , 2015 , 116, 358-65	5.3	76
151	A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. <i>Nanotechnology</i> , 2010 , 21, 355101	3.4	75
150	Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. <i>Nature Cell Biology</i> , 2019 , 21, 511-521	23.4	73
149	Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. <i>Annals of Oncology</i> , 2015 , 26, 2180-92	10.3	72
148	Ductal carcinoma in situ: to treat or not to treat, that is the question. <i>British Journal of Cancer</i> , 2019 , 121, 285-292	8.7	71
147	Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. <i>EMBO Molecular Medicine</i> , 2014 , 6, 212-25	12	71
146	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. <i>Breast Cancer Research</i> , 2014 , 16, R47	8.3	70
145	BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. <i>Nature Methods</i> , 2018 , 15, 134-140	21.6	68
144	Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. <i>Cancer Research</i> , 2010 , 70, 1700-10	10.1	67
143	A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 99-108	12.9	67
142	Further evidence for BRCA1 communication with the inactive X chromosome. <i>Cell</i> , 2007 , 128, 991-1002	56.2	67
141	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. <i>Cell Reports</i> , 2018 , 23, 2107-2118	10.6	67
140	Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. <i>Nature Communications</i> , 2017 , 8, 15981	17.4	66
139	Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. <i>Nature</i> , 2012 , 482, 538-41	50.4	66

138	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. <i>Cancer Research</i> , 2017 , 77, e62-e66	10.1	65
137	Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 13427-32	11.5	62
136	Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. <i>Cancer Research</i> , 2009 , 69, 2244-51	10.1	61
135	Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. <i>Experimental Cell Research</i> , 2007 , 313, 133-45	4.2	60
134	Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. <i>Nucleic Acids Research</i> , 2008 , 36, e13	20.1	59
133	Oncogene addiction: sometimes a temporary slavery. <i>Cancer Cell</i> , 2004 , 6, 535-8	24.3	56
132	A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. <i>Genome Research</i> , 2004 , 14, 188-96	9.7	55
131	Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. <i>Cell Reports</i> , 2015 , 10, 383-397	10.6	54
130	Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. <i>Oncogene</i> , 2004 , 23, 6047-55	9.2	54
129	Modeling metastatic breast cancer in mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2007 , 12, 191-203	2.4	53
128	Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. <i>Gastroenterology</i> , 2007 , 132, 1465-75	13.3	52
127	Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. <i>Cancer Research</i> , 2005 , 65, 8166-73	10.1	52
126	E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. <i>Cancer Discovery</i> , 2018 , 8, 498-515	24.4	51
125	Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. <i>Cellular and Molecular Life Sciences</i> , 2012 , 69, 223-45	10.3	51
124	Frat is dispensable for canonical Wnt signaling in mammals. <i>Genes and Development</i> , 2005 , 19, 425-30	12.6	51
123	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. <i>Cancer Research</i> , 2016 , 76, 6084-6094	10.1	50
122	Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours. <i>Nature Cell Biology</i> , 2016 , 18, 1346-1356	23.4	49
121	Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. <i>Nature Genetics</i> , 2017 , 49, 1219-1230	36.3	49

120	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. <i>International Journal of Cancer</i> , 2015 , 136, 1434-44	7.5	49
119	The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity. <i>Nature Communications</i> , 2018 , 9, 5406	17.4	49
118	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. <i>Cell Reports</i> , 2018 , 23, 100-111	10.6	47
117	BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. <i>BMC Cancer</i> , 2010 , 10, 654	4.8	46
116	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , 2021 , 53, 86-99	36.3	44
115	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	43
114	A preclinical mouse model of invasive lobular breast cancer metastasis. <i>Cancer Research</i> , 2013 , 73, 353-63	10.1	41
113	Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. <i>Cancer Research</i> , 2012 , 72, 2350-61	10.1	41
112	Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling. <i>Cancer Research</i> , 2013 , 73, 4937-49	10.1	40
111	Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 96-106	12.9	39
110	BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1398-1414	12	39
109	Xenofilter: computational deconvolution of mouse and human reads in tumor xenograft sequence data. <i>BMC Bioinformatics</i> , 2018 , 19, 366	3.6	39
108	Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. <i>Cancer Research</i> , 2007 , 67, 4648-56	10.1	38
107	Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 8632-7	11.5	37
106	Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool. <i>Stem Cells</i> , 2013 , 31, 1910-20	5.8	37
105	BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. <i>Cancer Research</i> , 2015 , 75, 732-41	10.1	36
104	Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. <i>Cancer Research</i> , 2010 , 70, 883-95	10.1	36
103	Towards understanding the role of cancer-associated inflammation in chemoresistance. <i>Current Pharmaceutical Design</i> , 2009 , 15, 1844-53	3.3	36

102	High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors. <i>Genome Research</i> , 2011 , 21, 2181-9	9.7	36
101	Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. <i>Annual Review of Cancer Biology</i> , 2019 , 3, 235-254	13.3	36
100	Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. <i>BioEssays</i> , 2011 , 33, 701-10	4.1	34
99	In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3. <i>Mechanisms of Development</i> , 1999 , 88, 183-94	1.7	34
98	Using the GEMM-ESC strategy to study gene function in mouse models. <i>Nature Protocols</i> , 2015 , 10, 1755-1858	18.5	32
97	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. <i>Nature Communications</i> , 2019 , 10, 397	17.4	31
96	PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma. <i>Cell Reports</i> , 2016 , 16, 2087-2101	10.6	31
95	Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. <i>BMC Cancer</i> , 2010 , 10, 455	4.8	31
94	Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression. <i>Oncogene</i> , 1999 , 18, 5982-90	9.2	31
93	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 773-791	19.4	31
92	ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets. <i>Nature Communications</i> , 2013 , 4, 2697	17.4	30
91	Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2+ breast cancer. <i>Pain</i> , 2015 , 156, 1424-1432	8	29
90	Genetically engineered mouse models of PI3K signaling in breast cancer. <i>Molecular Oncology</i> , 2013 , 7, 146-64	7.9	28
89	Mouse models for sporadic cancer. <i>Experimental Cell Research</i> , 2001 , 264, 100-10	4.2	28
88	Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547. <i>Cancer Research</i> , 2018 , 78, 5668-5679	10.1	27
87	Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal. <i>Stem Cells</i> , 2013 , 31, 1857-67	5.8	27
86	Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. <i>Cancer Research</i> , 2010 , 70, 520-31	10.1	27
85	Modeling therapy resistance in genetically engineered mouse cancer models. <i>Drug Resistance Updates</i> , 2008 , 11, 51-60	23.2	27

84	Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors. <i>Cancer Research</i> , 2019 , 79, 452-460	10.1	26
83	Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. <i>Journal of Pathology</i> , 2011 , 224, 10-21	9.4	25
82	Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE-deficient mice. <i>FASEB Journal</i> , 2006 , 20, 953-5	0.9	25
81	Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 54364-54377	3.3	24
80	Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. <i>Cell Cycle</i> , 2010 , 9, 3780-91	4.7	24
79	EZH2 Is Overexpressed in -like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4351-4362	12.9	23
78	BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny. <i>Genes and Development</i> , 2013 , 27, 39-51	12.6	23
77	BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres. <i>EMBO Journal</i> , 2015 , 34, 410-24	13	23
76	In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer. <i>EMBO Journal</i> , 2020 , 39, e102169	13	22
75	The use of mass spectrometry imaging to predict treatment response of patient-derived xenograft models of triple-negative breast cancer. <i>Journal of Proteome Research</i> , 2015 , 14, 1069-75	5.6	22
74	Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. <i>Current Opinion in Genetics and Development</i> , 2012 , 22, 21-7	4.9	22
73	Somatic structural rearrangements in genetically engineered mouse mammary tumors. <i>Genome Biology</i> , 2010 , 11, R100	18.3	22
72	Therapeutic options for triple-negative breast cancers with defective homologous recombination. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009 , 1796, 266-80	11.2	22
71	Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. <i>Cell Cycle</i> , 2008 , 7, 2647-53	4.7	22
70	Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. <i>Molecular Cell</i> , 2021 , 81, 3128-3144.e7	17.6	22
69	Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. <i>Molecular and Cellular Proteomics</i> , 2012 , 11, M111.013334	7.6	21
68	EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. <i>PLoS ONE</i> , 2012 , 7, e45248	3.7	21
67	Computational identification of insertional mutagenesis targets for cancer gene discovery. <i>Nucleic Acids Research</i> , 2011 , 39, e105	20.1	21

66	KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data. <i>BMC Research Notes</i> , 2010 , 3, 298	2.3	21
65	Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system. <i>Journal of Pathology</i> , 2011 , 224, 56-66	9.4	20
64	Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 21836-41	11.5	20
63	Mammary tumorigenesis through LPA receptor signaling. <i>Cancer Cell</i> , 2009 , 15, 457-9	24.3	20
62	Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance. <i>Molecular and Cellular Proteomics</i> , 2013 , 12, 1319-34	7.6	19
61	Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2. <i>Laboratory Investigation</i> , 2018 , 98, 117-129	5.9	18
60	Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance. <i>Scientific Reports</i> , 2013 , 3, 1949	4.9	18
59	Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach. <i>PLoS Computational Biology</i> , 2010 , 6, e1000631	5	18
58	Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells. <i>Oncotarget</i> , 2014 , 5, 11827-46	3.3	18
57	Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011 , 16, 41-50	2.4	17
56	Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS. <i>PLoS ONE</i> , 2013 , 8, e48324	3.7	17
55	Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division. <i>British Journal of Cancer</i> , 2018 , 118, 1586-1595	8.7	16
54	Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human. <i>American Journal of Pathology</i> , 2007 , 170, 377-87	5.8	16
53	Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin. <i>Nature Communications</i> , 2019 , 10, 3800	17.4	15
52	Conditional Pten knock-out mice: a model for metastatic pheochromocytoma. <i>Journal of Pathology</i> , 2009 , 217, 597-604	9.4	15
51	E-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer. <i>Journal of Pathology</i> , 2018 , 245, 456-467	9.4	15
50	Selected Alkylating Agents Can Overcome Drug Tolerance of G-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice. <i>Clinical Cancer Research</i> , 2017 , 23, 7020-7033	12.9	14
49	Characterization and functional analysis of the murine Frat2 gene. <i>Journal of Biological Chemistry</i> , 2004 , 279, 26967-74	5.4	14

48	Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors. <i>PLoS ONE</i> , 2013 , 8, e62113	3.7	13
47	Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer. <i>Oncotarget</i> , 2016 , 7, 63537-63548	3.3	13
46	A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis. <i>Journal of Pathology</i> , 2010 , 220, 34-44	9.4	12
45	MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. <i>Breast Cancer Research</i> , 2012 , 14, 324	8.3	10
44	TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development. <i>Genes and Development</i> , 2020 , 34, 179-193	12.6	10
43	SMARCAD1-mediated active replication fork stability maintains genome integrity. <i>Science Advances</i> , 2021 , 7,	14.3	10
42	p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2016 , 21, 81-88	2.4	9
41	Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases. <i>PLoS ONE</i> , 2014 , 9, e103177	3.7	9
40	Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol. <i>Cancer Prevention Research</i> , 2012 , 5, 1053-60	3.2	9
39	Studying drug resistance using genetically engineered mouse models for breast cancer. <i>Methods in Molecular Biology</i> , 2010 , 596, 33-45	1.4	9
38	Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. <i>Molecular Cell</i> , 2021 , 81, 4692-4708.e9	17.6	8
37	PARPi synthetic lethality derives from replication-associated single-stranded DNA gaps		8
36	Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining. <i>Cell Reports</i> , 2020 , 32, 108068	10.6	8
35	Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016 , 81, 141-150	3.9	7
34	Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents. <i>Molecular Oncology</i> , 2018 , 12, 953-971	7.9	7
33	Mouse models in the era of large human tumour sequencing studies. <i>Open Biology</i> , 2018 , 8,	7	7
32	Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. <i>Oncotarget</i> , 2017 , 8, 87638-87646	3.3	7
31	Functional Categorization of Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays. <i>Clinical Cancer Research</i> , 2020 , 26, 4559-4568	12.9	6

30	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system. <i>OncImmunology</i> , 2020 , 9, 1724049	7.2	6
29	BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling. <i>Journal of Pathology</i> , 2018 , 246, 41-53	9.4	6
28	Potential value of color-coded dynamic breast-specific gamma-imaging; comparing (99m)Tc-(V)-DMSA, (99m)Tc-MIBI, and (99m)Tc-HDP in a mouse mammary tumor model. <i>Applied Radiation and Isotopes</i> , 2010 , 68, 2117-24	1.7	6
27	The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice. <i>Current Opinion in Genetics and Development</i> , 2021 , 66, 57-62	4.9	6
26	Identifying transposon insertions and their effects from RNA-sequencing data. <i>Nucleic Acids Research</i> , 2017 , 45, 7064-7077	20.1	5
25	Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance. <i>Oncogene</i> , 2018 , 37, 1594-1609	9.2	5
24	Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGF β receptor I kinase. <i>Journal of Pathology</i> , 2015 , 235, 745-59	9.4	5
23	Intraductal cisplatin treatment in a -associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. <i>Oncotarget</i> , 2017 , 8, 60750-60763	3.3	4
22	Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. <i>Nature Communications</i> , 2021 , 12, 4360	17.4	4
21	Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms. <i>Cancer Research</i> , 2020 , 80, 1486-1497	10.1	3
20	Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. <i>Cancers</i> , 2021 , 13,	6.6	3
19	Glucocorticoids regulate cancer cell dormancy		3
18	Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum. <i>Cancers</i> , 2021 , 13,	6.6	3
17	Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice. <i>Journal of Pathology</i> , 2017 , 241, 511-521	9.4	2
16	GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019 , 24, 271-284	2.4	2
15	Tracking evolution of BRCA1-associated breast cancer. <i>Cancer Discovery</i> , 2012 , 2, 486-8	24.4	2
14	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts		2
13	PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair. <i>Cancers</i> , 2021 , 13,	6.6	2

12	A microfluidic cancer-on-chip platform predicts drug response using organotypic tumor slice culture. <i>Cancer Research</i> , 2021 ,	10.1	2
11	MYC promotes immune-suppression in TNBC via inhibition of IFN signaling		1
10	A BRCA1 coiled-coil domain variant disrupting PALB2 interaction promotes the development of mammary tumors and confers a targetable defect in homologous recombination repair. <i>Cancer Research</i> , 2021 ,	10.1	1
9	Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate. <i>Molecular and Cellular Proteomics</i> , 2021 , 20, 100078	7.6	1
8	Filling in the gaps in PARP inhibitor-induced synthetic lethality.. <i>Molecular and Cellular Oncology</i> , 2021 , 8, 2010512	1.2	0
7	Exogenous ER α Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019 , 24, 305-321	2.4	0
6	Models for angiogenesis: From fundamental mechanisms to anticancer treatment research. <i>Drug Discovery Today: Disease Models</i> , 2007 , 4, 75-82	1.3	
5	Functional genetic dropout screens and validation of candidate therapeutic targets using mouse mammary tumoroids.. <i>STAR Protocols</i> , 2022 , 3, 101132	1.4	
4	Identification and Characterization of Collaborating Oncogenes in Compound Mutant Mice 1998 , 15-30		
3	PARP Inhibitor ResistanceWhat Is Beyond BRCA1 or BRCA2 Restoration?. <i>Cancer Drug Discovery and Development</i> , 2015 , 453-471	0.3	
2	Abstract PR3: Patient derived BRCA1-deficient triple-negative breast cancer xenografts develop resistance to DNA damaging agents via genetic and epigenetic mechanisms. <i>Clinical Cancer Research</i> , 2012 , 18, PR3-PR3	12.9	
1	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. <i>Journal of Cell Biology</i> , 2013 , 202, 202201A57	7.3	